Patents Issued in October 6, 2020
  • Patent number: 10793579
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: October 6, 2020
    Assignee: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • Patent number: 10793580
    Abstract: The present invention relates to novel pyrazoloazepin-8-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: October 6, 2020
    Assignee: LEO Pharma A/S
    Inventors: Xifu Liang, Jens Larsen
  • Patent number: 10793581
    Abstract: The present invention relates to stereochemically defined polypropionates and methods for preparing and using the same. The stereochemically defined polypropionates may be useful in the synthesis of natural products and/or natural product-like libraries.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: October 6, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. Fang, Hyeong-wook Choi, Silvio Campagna, Steven Mathieu
  • Patent number: 10793582
    Abstract: Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 6, 2020
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Masahiro Okuyama, Kenji Fukunaga, Kenji Usui, Norimitsu Hayashi, Daisuke Iijima, Hideki Horiuchi, Nobuaki Fujimoto
  • Patent number: 10793583
    Abstract: Described herein are novel compounds and methods for the treatment and/or prevention of cerebral amyloidoses such as Alzheimer's disease (AD) and/or cerebral amyloid angiopathy (CAA).
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: October 6, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Robert Boyd
  • Patent number: 10793584
    Abstract: In order to provide a naphthobischalcogenadiazole derivative that can be used as an intermediate for producing a naphthobischalcogenadiazole compound into which a fluorine atom has been introduced, the naphthobischalcogenadiazole derivative in accordance with an aspect of the present invention is represented by a formula (I): where each of A1 and A2 is independently an oxygen atom, a sulfur atom, a selenium atom, or a tellurium atom; and each of X1 and X2 is independently a hydrogen atom, a halogen atom, a boronic acid group, a boronic acid ester group, a boronic acid diaminonaphthalene amide group, an N-methyliminodiacetic acid boronate group, a trifluoroborate salt group, or a triolborate salt group.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: October 6, 2020
    Assignees: Osaka University, Ishihara Sangyo Kaisha, Ltd.
    Inventors: Yutaka Ie, Yoshio Aso, Takuji Seo, Taichi Moriyama
  • Patent number: 10793585
    Abstract: Disclosed is a phosphoric acid diester salt which can suppress deterioration of charge-discharge characteristics of a power storage element, and can suppress the rise in internal resistance after storage at high temperature, a production method therefor, a non-aqueous electrolytic solution for a power storage element, and a power storage element. Disclosed is a phosphoric acid diester salt represented by the following chemical formula (1): wherein Mn+ represents a hydrogen ion, an alkali metal ion, an alkali earth metal ion, an aluminum ion, a transition metal ion, or an onium ion; R1 and R2 are different from each other and represent a hydrocarbon group having 1 to 10 carbon atoms, or a hydrocarbon group having 1 to 10 carbon atoms and having at least one of a halogen atom, a heteroatom, and an unsaturated bond; and n represents a valence.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: October 6, 2020
    Assignee: STELLA CHEMIFA CORPORATION
    Inventors: Toshitaka Sakaguchi, Sojiro Kon, Yoshifumi Katsura, Masashi Yamamoto, Tetsuo Nishida
  • Patent number: 10793586
    Abstract: The present invention provides a quaternary ammonium etidronate compound (QAE) comprising a quaternary ammonium cation and an etidronate anion, having the Formula I. A method for the preparation of such compounds is described by reacting a quaternary ammonium salt with an etidronic acid or salt thereof. Variable ratios of each reactant may also be used to form different QAE compounds. The quaternary ammonium etidronate compounds is useful in water treatment, cosmetic, hygiene, personal care, paint, coating, wood treatment, agrochemical, antimicrobial, disinfectant, or biocidal compositions; as the compound provides high anti-corrosive and biocidal properties; and low scaling properties. A water treatment composition is also described, having a QAE compound of Formula I and a water treating biocidal agent, useful in cooling towers and other recirculating water, or recreational water system.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: October 6, 2020
    Assignee: INNOVATIVE WATER CARE, LLC
    Inventors: Deqing Lei, Nidhi Rawat, Amber Khanzada
  • Patent number: 10793587
    Abstract: A method of enhancing the growth of an animal, as well as treating or preventing antimicrobial infections is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center such as amino acids or ?-hydroxy acids. The compounds are also useful for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: October 6, 2020
    Assignee: AKESO BIOMEDICAL, INC.
    Inventors: Dlawer Ala'Aldeen, Jafar Mahdavi, Panos Soultanas
  • Patent number: 10793588
    Abstract: The present invention relates to a crystalline form of a co-crystal of an inhibitor against sodium-glucose cotransporter 2 with L-proline, a method for preparing the same, a pharmaceutical composition comprising the same, and use thereof. Specifically, the present invention relates to a crystalline form of a co-crystal of an inhibitor against sodium-glucose cotransporter 2 represented by formula (1), i.e., (2S,3R,4R,5S,6R)-2-(3-(4-(((1R,3s,5S)-bicyclo[3.1.0]hexan-3-yl)oxy)benzyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, with L-proline, a method for preparing the same, a pharmaceutical composition comprising the same, and use thereof.
    Type: Grant
    Filed: May 27, 2017
    Date of Patent: October 6, 2020
    Assignees: JI LIN HUI SHENG BIO-PHARMACEUTICAL CO., LTD., BEIJING HUIZHIHENG BIOTECHNOLOGY CO., LTD.
    Inventors: Chutian Shu, Zhenhua Wang
  • Patent number: 10793589
    Abstract: The present invention relates to a newly developed resorcinarene-based amphipathic compound, a method for producing the same, and a method for extracting, solubilizing, stabilizing, crystallizing, or analyzing a membrane protein by using the same. In addition, compared to a conventional compound, the compound can efficiently extract, from a cell membrane, membrane proteins having a greater variety of structures and characteristics, and can stably store such membrane proteins for a long time in an aqueous solution. Therefore, the compound can be used to analyze the functions and structures of such membrane proteins. Analysis of the structures and functions of membrane proteins, being closely related to the development of new drugs, is one of the fields of greatest interest in biology and chemistry today.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: October 6, 2020
    Assignee: Industry-University Cooperation Foundation Hanyang University Erica Campus
    Inventors: Pil Seok Chae, Hazrat Hussain
  • Patent number: 10793590
    Abstract: Compounds of formula (I) or formula (II), compositions and methods useful for treating and/or preventing a fungal infections are provided. wherein the substituents are as defined in the appended claims.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: October 6, 2020
    Assignees: President and Fellows of Harvard College, Wisconsin Alumni Research Foundation, Universidad de Costa Rica
    Inventors: Ethan Van Arnam, Clarissa Sit, Antonio Ruzzini, Jon Clardy, Cameron Currie, Adrian Alberto Pinto-Tomas
  • Patent number: 10793591
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: October 6, 2020
    Assignee: Janssen BioPharma, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith
  • Patent number: 10793592
    Abstract: The present invention relates to the purification of target molecules like recombinant and/or biotherapeutic proteins. Activated carbon can be used to remove leachables and/or extractables resulting from disposable equipment employed in the process.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: October 6, 2020
    Assignee: Merck Patent GmbH
    Inventors: Romas Skudas, Klaus Adrian, Bianca Edlemann, Sven Andrecht, Wilson Moya
  • Patent number: 10793593
    Abstract: The present invention relates to a selectively soluble polymer capable of binding to one or more constituents in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and is rendered insoluble and precipitates out of solution upon a change in the process conditions. While in its solubilized state, the polymer is capable of binding to a selected entity within the stream such as impurities (DNA, RNA, host cell protein, endotoxins, etc.) in a cell broth and remains capable of binding to that entity even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered and further processed.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: October 6, 2020
    Assignee: EMD Millipore Corporation
    Inventor: Wilson Moya
  • Patent number: 10793594
    Abstract: Some embodiments include compounds that can inhibit the growth of bacterial and/or inhibit or reduce microbial infections caused by one or more microorganisms (e.g., Pseudomonas aeruginosa and Cryptococcus neoformans) and methods of using these compounds to treat microbial infection and outbreaks and/or to reduce the formation of biofilms. Other embodiments include synthesis of the compounds that can inhibit the growth of one or more microorganisms and/or inhibit or reduce microbial infections.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: October 6, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: William Leonard Scott, Martin James O'Donnell, Jack Geno Samaritoni
  • Patent number: 10793595
    Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: October 6, 2020
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, UNIVERSITY OF SOUTH FLORIDA
    Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
  • Patent number: 10793596
    Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I: These compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: October 6, 2020
    Assignee: Cara Therapeutics, Inc.
    Inventors: Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Robert Zhiyong Luo
  • Patent number: 10793597
    Abstract: The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof. The methods provide administering aromatic-cationic peptides in effective amounts to prevent, treat or ameliorate the disruption of mitochondrial oxidative phosphorylation in a cell such as that found in a subject suffering from, or predisposed to a mitochondrial disease or disorder. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for a mitochondrial disease or disorder, an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: October 6, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Patent number: 10793598
    Abstract: Fusion peptides and methods of inhibiting GrB-EHITSN or a fragment thereof are provided. The fusion peptides include an NPF peptide and a cell-permeable peptide operably connected thereto. Fusion peptides and methods of inhibiting activity of GrB-EHITSN or fragment thereof are provided. An aspect includes a fusion peptide comprising an isolated NPF peptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 2 and a cell-permeable peptide operably connected to the isolated NPF peptide, wherein the fusion peptide inhibits activity of GrB-EHITSN or a fragment thereof.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 6, 2020
    Assignee: Rush University Medical Center
    Inventors: Sanda Predescu, Dan Predescu
  • Patent number: 10793599
    Abstract: The present invention provides MPHOSPH1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: October 6, 2020
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Sachiko Yamashita, Tetsuro Hikichi
  • Patent number: 10793600
    Abstract: The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: October 6, 2020
    Assignee: HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH
    Inventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf W. Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Hüttel
  • Patent number: 10793601
    Abstract: Isolated peptides and pharmaceutical compositions comprising isolated peptides that bind to retinoblastoma binding protein 4 (RBBp4) and block the Spalt-Like Transcription Factor 4 (SALL4)-RBBp4 interaction are described. Methods of inhibiting binding of SALL4 to RBBp4 and methods of treating a subject having a disorder mediated by a dysregulation of SALL4 are also described.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: October 6, 2020
    Assignees: National University of Singapore, The Brigham and Women's Hospital, Inc., Agency for Science, Technology and Research
    Inventors: Bee Hui Liu, Daniel Geoffrey Tenen, Li Chai, Cheng San Brian Chia, Anders Poulsen
  • Patent number: 10793602
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: October 6, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Patent number: 10793603
    Abstract: A polysaccharide derivative has a partial structure represented by Formula (1) below. It is preferable that at least one of the amino acids that constitute X2 in Formula (1) below is a basic amino acid. (In the formula, X1 represents a residue obtained by removing the terminal amino group and the terminal carboxyl group from a neutral amino acid or an ?-aminoalkanoic acid, X2 represents a residue obtained by removing the terminal amino group and the terminal carboxyl group from a membrane-permeable peptide, X3 represents a hydroxyl group, an amino group, an alkoxyl group having 1 to 4 carbon atoms, or a benzyloxy group, a represents a number of 0 or 1, and b represents a number of from 0 to 50.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: October 6, 2020
    Assignees: JOSHO GAKUEN EDUCATIONAL FOUNDATION, ADEKA CORPORATION
    Inventors: Shinji Sakuma, Kohta Mohri, Ken-ichiro Hiwatari, Kyohei Ochiai
  • Patent number: 10793604
    Abstract: The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: October 6, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Loic Le Hir de Fallois, Greg Pacofsky, Alan Long, Charles Meng, Hyoung Ik Lee, Cyprian O. Ogbu
  • Patent number: 10793605
    Abstract: The present invention relates to ?-PNA monomers according to Formula I where substituent groups R1, R2, R3, R4, R5, R6, B and P are defined as set forth in the specification. The invention also provides methodology for synthesizing compounds according to Formula I and methodology for synthesizing PNA oligomers that incorporate one or more Formula I monomers.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: October 6, 2020
    Assignee: CARNEGIE MELLON UNIVERSITY
    Inventors: Danith H. Ly, Srinivas Rapireddy, Bichismita Sahu
  • Patent number: 10793606
    Abstract: Adeno associated viral (AAV) particles are emerging as useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: October 6, 2020
    Assignees: University of Florida Research Foundation, Incorporated, The UAB Research Foundation
    Inventors: Sergei Zolotukhin, Sanford L. Boye, Shannon E. Boye, Damien Marsic, Paul D. Gamlin
  • Patent number: 10793607
    Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: October 6, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Lucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes Petrus Maria Langedijk
  • Patent number: 10793608
    Abstract: Disclosed are hypersensitive-response eliciting peptides and non-hypersensitive response eliciting peptides that induce active plant responses, and that exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: October 6, 2020
    Assignee: PLANT HEALTH CARE, INC.
    Inventors: Zhongmin Wei, Gregory A. Zornetzer
  • Patent number: 10793609
    Abstract: Provided herein are synthetic pathways from Escherichia coli and Vibrio cholerae genes for the production of new, synthetic nonribosomal peptides, and methods and compositions comprising the same. Some aspects of the present disclosure are directed to modified bacterial cells comprising a compressed biosynthetic pathway that comprises (a) biosynthetic genes obtained from one species encoding enzymes active in the bioassembly of a nonribosomal molecule, (b) biosynthetic genes obtained from another species encoding enzymes active in the bioassembly of a nonribosomal molecule that is different from the nonribosomal molecule of (a). In some embodiments, the biosynthetic genes of (a) are Escherichia coli biosynthetic genes and may include entD gene, an entC gene, an entE gene, an entB gene and an entA gene. In some embodiments, the biosynthetic genes of (b) are Vibrio cholera biosynthetic genes and may include a vibH gene and a vibF gene.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: October 6, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Sara da Luz Areosa Cleto
  • Patent number: 10793610
    Abstract: Compositions having pesticidal activity and methods for their use are provided. Compositions include isolated and recombinant polypeptide sequences having pesticidal activity, recombinant and synthetic nucleic acid molecules encoding the pesticidal polypeptides, DNA constructs comprising the nucleic acid molecules, vectors comprising the nucleic acid molecules, host cells comprising the vectors, and antibodies to the pesticidal polypeptides. Nucleotide sequences encoding the polypeptides provided herein can be used in DNA constructs or expression cassettes for transformation and expression in organisms of interest, including microorganisms and plants. The compositions and methods provided herein are useful for the production of organisms with enhanced pest resistance or tolerance. Transgenic plants and seeds comprising a nucleotide sequence that encodes a pesticidal protein of the invention are also provided. Such plants are resistant to insects and other pests.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: October 6, 2020
    Assignee: AgBiome, Inc.
    Inventors: Jessica Parks, Kira Bulazel Roberts, Rebecca E. Thayer
  • Patent number: 10793611
    Abstract: The disclosure provides nucleic acids encoding variant polypeptides having pesticidal activity against insect pests, including Lepidoptera and Diptera. Particular embodiments provide isolated nucleic acids encoding Cyt1A variant polypeptides, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, particularly Diptera pests.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: October 6, 2020
    Assignee: Universidad Nacional Autónoma de México
    Inventors: Maria Alejandra Bravo de la Parra, Mario Soberón Chavez
  • Patent number: 10793612
    Abstract: This disclosure concerns methods for the design of synthetic nucleic acid sequences that encode polypeptide amino acid repeat regions. This disclosure also concerns the use of such sequences to express a polypeptide of interest that comprises amino acid repeat regions, and organisms comprising such sequences.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: October 6, 2020
    Assignee: Dow AgroSciences LLC
    Inventors: Donald J. Merlo, Ignacio Larrinua, Scott Bevan
  • Patent number: 10793613
    Abstract: The present disclosure encompasses compositions and methods for targeted cytokine delivery. The compositions disclosed herein comprise a cytokine linked to a ligand and may improve immunotherapy by limiting side effects associated with immunotherapy.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: October 6, 2020
    Inventors: Alexander Sasha Krupnick, Eric Reed Lazear, Daved Henry Fremont
  • Patent number: 10793614
    Abstract: Peptide-based neurokinin antagonists of fish reproduction are disclosed. Compositions comprising antagonists of fish neurokinin and methods of inhibiting or delaying puberty, fish maturation or reproduction processes using these compounds are also provided.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: October 6, 2020
    Assignee: Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd.
    Inventors: Berta Levavi-Sivan, Chaim Gilon
  • Patent number: 10793615
    Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 6, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Ravi Nargund, Paul E. Carrington, Tomi Sawyer, Qiaolin Deng, Antonello Pessi, Elisabetta Bianchi, Federica Orvieto
  • Patent number: 10793616
    Abstract: Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder. The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment. The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: October 6, 2020
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Tim Schnyder
  • Patent number: 10793617
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: October 6, 2020
    Assignee: ONCOIMMUNE, INC.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • Patent number: 10793618
    Abstract: The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: October 6, 2020
    Assignee: COLZYX AB
    Inventors: Matthias Mörgelin, Suado Abdillahi
  • Patent number: 10793619
    Abstract: Provided are compositions and methods for preparing a cell suitable for producing a bispecific antibody. A plurality of eukaryotic cells are incubated with an agent under conditions to allow the cells to arrest at G1/S phase. The agent is then removed from the cells and the cells are transfected with a first vector comprising a sequence encoding a first monovalent antigen-binding unit having specificity to a first antigen and a second vector comprising a sequence encoding a second monovalent antigen-binding unit having specificity to a second antigen. A cell is identified from the plurality of cells that expresses both the first and the second antigen-binding units.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: October 6, 2020
    Assignee: Wuhan YZY Biopharma Co., Ltd.
    Inventors: Pengfei Zhou, Jing Zhang, Rui Wang, Xiang Zhou, Xiaoyan Liu, Lingli Hu, Sisi Fu, Hui Zhong
  • Patent number: 10793620
    Abstract: The invention refers to a non-therapeutic method for producing antigen-specific B cells by using the adoptive cell transfer of primed B cells, especially of spleen cells including B cells of a previously immunized non-human animal and by administering an antigen of interest to a naïve non-human animal.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: October 6, 2020
    Assignee: BIOGENES GMBH
    Inventor: Detlef Schmechel
  • Patent number: 10793621
    Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: October 6, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Hubert Kettenberger, Christian Klein, Klaus-Peter Kuenkele, Joerg-Thomas Regula, Wolfgang Schaefer, Manfred Schwaiger, Claudio Sustmann
  • Patent number: 10793622
    Abstract: The invention provides a three-step chromatography process for small and large-scale purification of proteins, specifically monoclonal antibodies, using only four buffer solutions made from a mother solution.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: October 6, 2020
    Assignee: SANOFI
    Inventors: Didier Duthe, Celine Hemet, Laure Landric-Burtin, Benoit Mothes
  • Patent number: 10793623
    Abstract: The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: October 6, 2020
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Samuel Lai, M. Gregory Forest, Christine Henry, Timothy Wessler, Alexander Chen, Jennifer Schiller, Jay Newby
  • Patent number: 10793624
    Abstract: Provided herein are antibodies that bind Fagales allergens, Fagales related allergens, birch pollen, or Bet v 1, compositions comprising the antibodies, nucleic acids encoding the antibodies, and methods of using the antibodies. According to certain embodiments, the antibodies are fully human monoclonal antibodies that bind to Bet v 1. The antibodies are useful for binding Bet v 1 in vivo, thus preventing binding of the allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the Fagales allergens in sensitized individuals.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: October 6, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jamie M. Orengo, Andrew J. Murphy, Ashok T. Badithe, Vishal Kamat, Yashu Liu
  • Patent number: 10793625
    Abstract: The present invention relates to the field of osteoarthritis. More specifically, the present invention provides compositions and methods useful for treating or preventing osteoarthritis. In one embodiment, a method for treating or preventing osteoarthritis in a patient comprises the step of administering to the patient a therapeutically effective amount of a transforming growth factor beta (TGF-beta) inhibitor.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: October 6, 2020
    Assignee: The Johns Hopkins University
    Inventor: Xu Cao
  • Patent number: 10793626
    Abstract: Subject matter of the present invention is an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold binding to the C-terminal portion of ADM, the aa 43-52 of ADM (SEQ ID NO: 1): APRSKISPQGY-NH2 for use in a therapy of cancer. Subject matter of the present invention is anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in the treatment of cancer according to claim 1 wherein said anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold requires the presence of a C-terminally amidated tyrosine residue within the C-terminal portion of ADM, the aa 43-52 of ADM (SEQ ID NO: 1): APRSKISPQGY-NH2, for binding.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 6, 2020
    Assignee: ANGIOBIOMED GMBH
    Inventor: Andreas Bergmann
  • Patent number: 10793627
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: October 6, 2020
    Assignees: argenx BVBA, Université Catholique de Louvain
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • Patent number: 10793628
    Abstract: Methods and compositions for treatment and therapy of cancer are provided. Specifically, antagonists specific for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B are provided. Potent neutralizing antibodies specific for IL-17RB and methods for their manufacture and use are disclosed. The invention also relates to antisense, RNAi and shRNA compositions for the prevention and treatment of cancer, in particular breast cancer and pancreatic cancer.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: October 6, 2020
    Assignee: Academia Sinica
    Inventors: Wen-Hwa Lee, Jin-Yuh Shew, Che Ma, Chia-Lin Chen, Wen-Hsin Lee, Chun-Kai Huang, Heng-Hsiung Wu